Stockreport

VolitionRx Limited Announces the First Sale of the Nu.Q® Cancer Assays for Clinical Certification in Preparation for Routine Clinical Use

VolitionRX Limited  (VNRX) 
NASDAQ:AMEX Investor Relations: ir.volitionrx.com
PDF HENDERSON, Nev., Nov. 25, 2025 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition"), a multi-national epigenetics company, today announces the first sal [Read more]